Short answer
Replimune Group, Inc. (REPL) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 fiscal 2026 results for quarter ended September 30, 2026 announced October 28, 2026.
Replimune Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended September 30, 2026 announced October 28, 2026
- Corporate updates included alongside financial results
- Detailed figures and management commentary in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Fiscal Q2 2027 launch underway: TUDRIQEV delivered October 6, with more than 15 institutions prescribing
- Commercial traction: Replimune engaged over 70% of its initial 200 priority accounts, with formulary placements emerging
- Cash $307.8M versus $268.9M at March 31, 2026, supported by $141.0M equity proceeds and $15.0M debt draw
- Q2 net loss $57.1M versus $83.1M prior year, while R&D declined to $34.4M from $57.9M
- Key risk: accelerated approval depends on clinical benefit verification in the ongoing IGN YTE-3 Phase 3 trial
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Replimune Group, Inc. 8-K filings
Get the next REPL 8-K as it lands
Follow REPL for push alerts, or ask the research agent what this filing means.